Sara Taylor

604 total citations
16 papers, 361 citations indexed

About

Sara Taylor is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Sara Taylor has authored 16 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in Sara Taylor's work include Breast Cancer Treatment Studies (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). Sara Taylor is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). Sara Taylor collaborates with scholars based in Canada, United States and Australia. Sara Taylor's co-authors include Kathleen I. Pritchard, Marguerite Ennis, Pamela J. Goodwin, Jarley Koo, Maureen Trudeau, Nicky Hood, Stephen Chia, Mark Clemons, Percy Ivy and Natasha B. Leighl and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Sara Taylor

15 papers receiving 354 citations

Peers

Countries citing papers authored by Sara Taylor

Since Specialization

Citations

This map shows the geographic impact of Sara Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Taylor more than expected).

Fields of papers citing papers by Sara Taylor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Taylor. The network helps show where Sara Taylor may publish in the future.

Co-authorship network of co-authors of Sara Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Taylor. A scholar is included among the top collaborators of Sara Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Taylor. Sara Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast. 2025 ·Journal of Clinical Oncology ·David W. Cescon, Moira Rushton, Nathalie LeVasseur, Michelle B. Nadler, Daniel Rayson, Brooke E. Wilson, Sara Taylor, Rossanna C. Pezo, Arif Awan, Vikaash Kumar, (unknown), John Hilton, Stephen Chia, Philippe L. Bédard, (unknown), Wei Tu, (unknown), Philippe Jamme, Elia Aguado-Fraile, Lesley Seymour	1
2	EV257/#1106 Upgrade: phase 1 trial of the NaPi2b-directed dolaflexin antibody drug conjugate UpRi in combination with carboplatin in patients with platinum-sensitive ovarian cancer (PSOC) 2024 ·Claire F. Friedman, Charles Anderson, John P. Hays, Nehal J. Lakhani, Joseph Buscema, Erika Hamilton, Sara Taylor, (unknown), Noelle Cloven, (unknown), (unknown), (unknown), Theresa L. Werner	1
3	Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076) 2022 ·Gynecologic Oncology ·Debra L. Richardson, Erika Hamilton, Minal Barve, Charles Anderson, Sara Taylor, Nehal J. Lakhani, Joseph Buscema, Anthony W. Tolcher, Corrine Zarwan, Theresa L. Werner, John L. Hays, Rebecca C. Arend, (unknown), Emily Putiri, Patricia Bernardo, Robert A. Burger, Ursula A. Matulonis	12
4	Survival following locoregional recurrence in breast cancer by clinical subtype. 2021 ·Journal of Clinical Oncology ·Kirsten Allen, Caroline Lohrisch, (unknown), (unknown), (unknown), Alan Nichol, Sara Taylor	0
5	Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer. 2021 ·Journal of Clinical Oncology ·Debra L. Richardson, Erika Hamilton, Ana Oaknin, Leslie M. Randall, Susana Banerjee, Sara Taylor, Linda Mileshkin, Robert L. Coleman, Bradley J. Monk, Mansoor Raza Mirza, Patricia Bernardo, Rebecca Mosher, Valerie M. Jansen, Antonella Savarese, Toon Van Gorp, Radosław Mądry, Isabelle Laure Ray-Coquard, Nicole Concin	9
6	Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm–Gotland cancer registry 2018 ·Breast Cancer Research and Treatment ·Claudette Falato, Sara Taylor, Robert Szulkin, (unknown), Louise Eriksson, Anastasios Sofiadis, Irma Fredriksson, Johan Hartman, Jonas Bergh, Theodoros Foukakis	4
7	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer 2017 ·Breast Cancer Research ·Stephen Chia, Susan Ellard, Mihaela Mates, Stephen Welch, Catalin Mihalcioiu, Wilson H. Miller, Karen A. Gelmon, Caroline Lohrisch, Vikaash Kumar, Sara Taylor, Linda Hagerman, Rachel Goodwin, Tao Wang, Shingo Sakashita, Ming‐Sound Tsao, Elizabeth A. Eisenhauer, Penelope A. Bradbury	32
8	Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls 2017 ·Breast Cancer Research and Treatment ·Ana Elisa Lohmann, Marguerite Ennis, Sara Taylor, Pamela J. Goodwin	17
9	Clinicians identify high need to increase their genomic literacy to applied cancer genomics 2016 ·Annals of Oncology ·Janessa Laskin, Đặng Thị Cẩm Hà, (unknown), Alexandra Fok, Karen A. Gelmon, (unknown), (unknown), (unknown), Cheryl Ho, Daniel J. Renouf, Howard J. Lim, Christine Simmons, Sara Taylor, Anna V. Tinker, John Paul McGhie, Steven J.M. Jones, Marco A. Marra, Peter A. Chow-White	1
10	A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer 2013 ·European Journal of Cancer ·(unknown), (unknown), Susan Ellard, Caroline Lohrisch, Karen A. Gelmon, Tamara Shenkier, Diego Villa, Howard J. Lim, Sophie Sun, Sara Taylor, Morag Taylor, (unknown), Malcolm Hayes, Diana Beşliu-Ionescu, Carl Yoshizawa, Calvin Chao, Stuart Peacock, Stephen Chia	44
11	A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. 2013 ·Journal of Clinical Oncology ·Stephen Chia, Susan Ellard, Mihaela Mates, Stephen Welch, Catalin Mihalcioiu, Wilson H. Miller, Karen A. Gelmon, Caroline Lohrisch, Vikaash Kumar, Sara Taylor, Linda Hagerman, Elizabeth A. Eisenhauer, Penelope Ann Bradbury	1
12	A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers. 2012 ·Journal of Clinical Oncology ·(unknown), (unknown), Susan Ellard, Caroline Lohrisch, Karen A. Gelmon, (unknown), Diego Villa, Howard J. Lim, Sophie Sun, Sara Taylor, Marianne Taylor, (unknown), Malcolm Hayes, Diana Beşliu-Ionescu, (unknown), (unknown), Carl Yoshizawa, Calvin Chao, Stuart Peacock, Stephen Chia	2
13	Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations 2011 ·Journal of Clinical Oncology ·Pamela J. Goodwin, Marguerite Ennis, Kathleen I. Pritchard, Maureen Trudeau, Jarley Koo, Sara Taylor, Nicky Hood	157
14	A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium 2010 ·The Oncologist ·Sara Taylor, Stephen Chia, Susan Dent, Mark Clemons, Mark Agulnik, (unknown), Lisa Wang, Amit M. Oza, Percy Ivy, Kathleen I. Pritchard, Natasha B. Leighl	53
15	Abstract A55: A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors 2009 ·Molecular Cancer Therapeutics ·Lillian L. Siu, Kyriakos P. Papadopoulos, Steven R. Alberts, Sara Taylor, Amita Patnaik, Eric X. Chen, Anthony W. Tolcher, (unknown), Lixin Lang, Christoph M. Ahlers, Kelly L. Bennett, Jan M. Van Tornout	13
16	A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium 2009 ·Journal of Clinical Oncology ·Sara Taylor, (unknown), Susan Dent, Mark Clemons, (unknown), (unknown), Amit M. Oza, Percy Ivy, Kathleen I. Pritchard, Natasha B. Leighl	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact